IL1A and cryopyrin-associated periodic syndrome: Table 2 illustrates the most relevant studies supporting the maximum evidence level for the use of IL-1 blockers in the main monogenic autoinflammatory diseases (crFMF, TRAPS, HIDS/MKD, and CAPS) and PFAPA syndrome and includes the doses used in pediatric and adult patients.